Axogen Q3 revenue $41.3M (+12% YoY); maintains FY2023 guidance $154-159M

Axogen, Inc.

2023-Q3 EPS reported -$0.42 revenue$116,090,000

Revenue $41.3M (+12% YoY); scheduled non-trauma grew ~20%, emergent trauma mid-single digits.
Net loss $4.1M ($0.10/sh); adjusted net income $0.7M ($0.01/sh); Adj. EBITDA $2.4M vs $0.4M.
Gross margin 80.5% (down from 83.3%); FY2023 gross margin expected ~80%.
Cash & investments $38.6M; new processing facility began tissue processing in Aug.
Core Accounts 372 (+12% YoY); revenue from Core Accounts now ~65% of total.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axogen, Inc. reported full year 2023 results: revenue $154 million to $159 million. Guidance reaffirmed.

Period: full year 2023
Revenue: $154 million to $159 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Management is maintaining full-year 2023 revenue guidance in the range of $154 million to $159 million, which represents annual growth of 11% - 15%.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axogen, Inc. reported third quarter ended September 30, 2023 results: net income Net loss of $4.1 million, EPS $0.10 per share.

Period: third quarter ended September 30, 2023
Net income: Net loss of $4.1 million
EPS: $0.10 per share
Result: reported results

Exact text from the filing

Revenue was $41.3 million during the third quarter, an increase of approximately 12% over the third quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axogen, Inc. reported third quarter ended September 30, 2023 results: net income Net loss of $4.1 million, EPS $0.10 per share.

Period: third quarter ended September 30, 2023
Net income: Net loss of $4.1 million
EPS: $0.10 per share
Result: reported results

Exact text from the filing

Net loss of $4.1 million, or $0.10 per share, compared to net loss of $4.3 million, or $0.10 per share in the third quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-23-000146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.